I just don't get the numbers these guys are spruiking. From "1.2 Rationale" of the upcoming meeting agenda they say they received approx US$105 million on 29 March (and then provide A$156 million as the conversion, which equates to FX rate of approx $0.67, which matches the rate of the day), and final payment of US$16 million on 29 Sept (no conversion offered). The FX rate on 29 Sept was closer to $0.64, but even using their previous conversion number ($0.67) the second tranche equates to approx A$23.8 million. So total sale is approx A$179.8 million, meaning their intended return of 89.4% would be approx $160.7 million. Or if we use the $0.64 exchange rate of 29 Sept ($US16 mill = A$25 mill), total sale is $181 million, 89.4% return is approx A$161.8 million.
So how do they arrive at a return to shareholders of only A$154,700,426?
And why the 65/35 split on Capital/Dividend return? Surely a greater Capital return is in most shareholder's best interests? The former may or may not be a CGT event for some shareholders, but the later will most definitely be a tax headache for most. Anyone know if this is driven by ATO requirements?
- Forums
- ASX - By Stock
- DNK
- Ann: Proposed return of 42 cents per share to shareholders
Ann: Proposed return of 42 cents per share to shareholders, page-8
-
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DNK (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $151.0M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DNK (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online